A study reinforces the contribution of S6K1 kinase in obesity and aging
IDIBELL-Bellvitge Biomedical Research Institute News Feb 22, 2017
EPRS phosphorylation mediates S6K1–dependent metabolic responses related to obesity and aging.
Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and Barcelona University (UB) Dr. George Thomas, head of the Metabolism and Cancer research group, and Dr. Sara Kozma, reported in the journal Nature, on the role of S6K1 in re–directing glutamyl–prolyl tRNA synthetase (EPRS) from inhibition of translation to transport fatty acids. The study was carried out in collaboration with researchers from Cleveland Clinic and Illinois University, and could potentially lead to the development of biomarkers and targeted therapies against obesity and aging.
Previous studies by Drs. Thomas and Kozma had shown that S6K1 plays a critical role in fat tissue expansion by transcriptionally regulating the differentiation of mesenchymal stem cells (MSCs) into adipocytes. As Dr. Thomas explained ÂIn the meantime, Paul Fox contacted us proposing a possible connection between S6K1 and the glutamyl–prolyl–tRNA snythetase (EPRS), together we found that that S6K1 phosphorylation is required to release EPRS from its canonical role in protein synthesis to form the interferon gamma inhibitor of translation (GAIT) complex, which blocks the translation of interferon regulated genesÂ.
ÂThis change of function is key, since we also found that EPRS mediates the localization of the fatty acid transport protein 1 (FATP1) to the membrane, stimulating the uptake of long chain fatty acidsÂ, adds Dr. Kozma. ÂThis confirmed a dual role of S6K1 in contributing to adiposity and aging. Indeed, mice with phospho–deficient EPRS present the same physical characteristics (phenotype) as S6K1–deficient mice: low body weight, reduced adipose tissue mass, and increased lifespan. These results reinforce the concept that S6K1 may serve as a predictor of obesity or as a drug target to suppress obesity.Â
Dr. Kozma is currently collaborating with Dr. José Manuel Fernández–Real of the CIBERobn research group at the Hospital of Girona ÂJosep Trueta and IDIBGI, in a project funded by La Marató de TV3 to obtain fat tissue samples to validate these results in humans and develop new biomarkers of adipose tissue expansion.
Go to Original
Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and Barcelona University (UB) Dr. George Thomas, head of the Metabolism and Cancer research group, and Dr. Sara Kozma, reported in the journal Nature, on the role of S6K1 in re–directing glutamyl–prolyl tRNA synthetase (EPRS) from inhibition of translation to transport fatty acids. The study was carried out in collaboration with researchers from Cleveland Clinic and Illinois University, and could potentially lead to the development of biomarkers and targeted therapies against obesity and aging.
Previous studies by Drs. Thomas and Kozma had shown that S6K1 plays a critical role in fat tissue expansion by transcriptionally regulating the differentiation of mesenchymal stem cells (MSCs) into adipocytes. As Dr. Thomas explained ÂIn the meantime, Paul Fox contacted us proposing a possible connection between S6K1 and the glutamyl–prolyl–tRNA snythetase (EPRS), together we found that that S6K1 phosphorylation is required to release EPRS from its canonical role in protein synthesis to form the interferon gamma inhibitor of translation (GAIT) complex, which blocks the translation of interferon regulated genesÂ.
ÂThis change of function is key, since we also found that EPRS mediates the localization of the fatty acid transport protein 1 (FATP1) to the membrane, stimulating the uptake of long chain fatty acidsÂ, adds Dr. Kozma. ÂThis confirmed a dual role of S6K1 in contributing to adiposity and aging. Indeed, mice with phospho–deficient EPRS present the same physical characteristics (phenotype) as S6K1–deficient mice: low body weight, reduced adipose tissue mass, and increased lifespan. These results reinforce the concept that S6K1 may serve as a predictor of obesity or as a drug target to suppress obesity.Â
Dr. Kozma is currently collaborating with Dr. José Manuel Fernández–Real of the CIBERobn research group at the Hospital of Girona ÂJosep Trueta and IDIBGI, in a project funded by La Marató de TV3 to obtain fat tissue samples to validate these results in humans and develop new biomarkers of adipose tissue expansion.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries